Summary Blast cells obtained from 104 children with untreated acute lymphoblastic leukaemia were analysed for the expression of P-glycoprotein (P-170) and glutathione S-transferase (GST-it) using immunohistochemistry. Expression of P-170 was detected in 36 of 104 patients (35%) and increased GST-i was seen in 52 patients (50%). Coexpression of both resistance proteins was observed in 22 leukaemias (21 %), whereas no evidence of the resistance markers was found in 38 cases (37%). In patients with P-170-positive leukaemic cells, a significantly lower probability of remaining in first continuous complete remission (CCR) was observed when compared with patients with P-I 70-negative tumours (P < 0.05J. However, only a trend for a more frequent expression of P-170 was found in the leukaemic cells of patients who experienced relapses (P = 0.099). Overexpression of GST-i was correlated with a higher relapse rate (P = 0.001) and a lower probability of remaining in first CCR (P = 0.01). Expression of P-170 and GST-i was independent of sex, FAB type, immunological subtype and initial blast cell count. The multivariate analysis indicated that only the expression of P-170 is an unfavourable prognostic factor for children with acute lymphoblastic leukaemia in addition to the prognostic clinical factors.
The results of chemotherapy on childhood acute lymphoblastic leukaemia (ALL) have been markedly improved during the past decade (Riehm et al., 1992) . The remission rate of patients treated with chemotherapy is more than 95%, and the long-term disease-free survival rate about 75%. In spite of these excellent results, 25% of the patients will experience a relapse with a poor prognosis. The search for risk factors to define patients at high risk of relapse who need a different or more aggressive therapy is thus a current problem.
Primary resistance to chemotherapeutic agents may be an important reason for relapses in ALL. During the past few years, the phenomenon of multidrug resistance (MDR) has been described, and some of its molecular aspects have been clarified (Endicott & Ling, 1989) . The MDR phenotype is characterised by cross-resistance to a range of widely used chemotherapeutic agents (e.g. anthracyclines, vinca alkaloids and epipodophyllotoxins). Frequently, MDR cells overexpress a transmembrane 170 kDa protein known as P-glycoprotein or P-170. P-glycoprotein-mediated drug resistance results in reduced drug accumulation in tumour cells as a result of increased efflux. Results obtained in different tumour types confirm the significance of the expression of P-170 for the clinical drug resistance (Chan et al., 1990; Volm et al., 1992a) . Some reports also indicate that P-170 expression may influence the therapeutic outcome in acute leukaemia (Pirker et al., 1991; Campos et al., 1992; Goasguen et al., 1993) . However, the number of patients included in ALL studies was small and the prognostic value of P-170 in childhood ALL has been not unequivocally clarified. Fur- thermore, not all multidrug-resistant tumours express P-170, so that refractoriness to chemotherapy can only partly be explained by the expression of P-170. This suggests that other mechanisms are also implicated in the acquisition of resistance. For instance, glutathione S-transferases are isoenzymes which conjugate glutathione with various xenobiotics (Black & Wolf, 1991) . These proteins may therefore play an important role in the detoxification of drugs (e.g. cyclophosphamide and anthracyclines) which are involved in ALL therapy.
Therefore, the aim of the present investigation was to assess the prognostic value of P-glycoprotein and glutathione S-transferase x in a retrospective study of 104 children with untreated non-B-acute lymphoblastic leukaemia using a immunohistochemical method. (Zintl et al., 1993) and ALL-BFM-90 (Riehm et al., 1992) ]. These treatment protocols consist of induction therapy with prednisone, vincristine, daunorubicin and L-asparaginase followed by consolidation therapy with cyclophosphamide, cytarabine, 6-mercaptopurine and intrathecal methotrexate (MTX). Patients included in study ALL-VII/8 1 (66 patients) and ALL-VIII/87 (22 patients) received intermediate-dose intravenously MTX (0.5 or 1 g m-2); patients included in study ALL-BFM-90 (16 patients) received high-dose MTX (5 g mr-2). Maintenance therapy was performed with oral 6-mercaptopurine (daily) and methotrexate (weekly) for up to 2 years after starting therapy. The different therapeutical procedures had no significant effects on the probability of remaining in continuous complete remission of the patients included in our study (P= 0.11).
Materials and methods

Patients and definitions
Leukaemic cells Cell samples were collected in heparinised flasks and mononuclear cells were isolated by Ficoll-Hypaque density gradient centrifugation. After washing twice in culture medium (RPMI-1640) the cells were cryopreserved in liquid nitrogen with 10% dimethylsulphoxide and 5% fetal calf serum using a programmed freezer. All cell samples contained at least 80% blast cells, examined by May-GriiwaldGiemsa staining.
Immunohistochemical methods For measuring P-glycoprotein (P-170) and glutathione Stransferase i (GST-r) cell samples were resuspended in Hanks' balanced salt solution (Biochrom, Berlin, Germany) and the viability of cells was tested by staining with methylene blue. Cell suspensions were centrifuged with a Cytospin II (Shandon, Frankfurt, Germany), resulting in a cell monolayer. After air drying the cells were fixed in ice-cold acetone for 10 min and stored at -20°C. Immunohistochemical investigations were performed using the streptavidin-biotin peroxidase complex method (Volm et al., 1988) . Cell preparations were briefly preincubated with hydrogen peroxide (0.3%; 15 min), unlabelled streptavidin (dilution 1: 50, 15 min) and non-immune normal serum. For the detection of P-170 we used the murine monoclonal antibody C 219 (Isotopendiagnostik, Dreieich, Germany) with specificity to an internal epitope of P-170 as the primary antibody. The final antibody concentration was 10 gsg ml-'.
A rabbit polyclonal antibody (GST-n, dilution 1:2,000; kindly provided by Dr K. Satoh, University School of Medicine, Hirosaki, Japan) was used for the detection of GST-7t. The primary antibodies were applied for 16 h at 4°C in a moist chamber. After three washes in phosphate-buffered saline (PBS) the cells were incubated for 30 min with biotinylated sheep anti-mouse IgG (Amersham, Braunschweig, Germany) for the detection of P-170 and with goat anti-rabbit IgG (Dianova, Hamburg, Germany) for the detection of GST-r (both diluted 1:50 with 5% normal human serum). Afterwards, the streptavidin-biotinylated peroxidase complex (Amersham; 1:100, 30 min) was added. Peroxidase activity was made visible with 3-amino-9-ethylcarbazole (15 min), which gives a red -brown reacting product. Counterstaining was performed with haematoxylin and the sections were mounted with glycerol gelatine. Negative controls were obtained firstly, omitting the primary antibodies and secondly by repeating all steps except for substitution the primary antibody by an irrelevant antibody. Positive controls for P-1 70 were performed using 40-fold doxorubicin-resistant L1210 mouse leukaemic cells which have a high expression of P-1 70, and as positive controls for GST-ir detection we used the 300-fold doxorubicin-resistant murine sarcoma cell line S180/DOX (Volm et al., 1988; Efferth et al., 1992) .
Three observers (M.V., H.G. & A.S.) independently evaluated and interpreted the results of immunohistochemical staining without knowing the clinical data. The evaluations were in agreement in 90% of the samples. The remaining patients were re-evaluated. Five hundred cells were counted in each sample. Patients were considered to positive for P-l 70-expression if at least 1% of the leukaemic cells were positively stained.
Because positive immunostaining was found not only in malignant cell populations but also in macrophages (Schlaifer et al., 1990) we distinguished between tumour cells and macrophages using MAb CD68 (Dako-CD 68, Kpl, Dakopats, Copenhagen, Denmark). In addition, the cells were judged by staining with haematoxylin for morphological criteria of leukaemic cells. Staining for GST-c was classified only on the basis of intensity (0 = negative, 1 = weak, 2 = moderate, 3 = high). Since GST-n was expressed at a baseline level in all cells, values of 0 and 1 were considered to negative, values of 2 and 3 positive.
Statistical analyses
We used Fisher's exact test to examine whether there is a correlation between clinical data, resistance markers and relapse rates. Life table analyses according to Kaplan and Meier (1956) were performed for relapse-free intervals; the groups were compared by log-rank tests.
The prognostic influence of clinical and molecular parameters was assessed by multivariate regression methods (Cox model; Cox, 1972) as described by Byar (1982) .
Results
In the present study 104 patients with untreated non-B-type acute lymphoblastic leukaemic were analysed using immunohistochemistry for the expression of P-glycoprotein (P-170) and glutathione S-transferase x (GST-n) in relationship to their therapy outcome. The patients' data are given in Table  I . The prognosis of the patients is largely determined by the initial peripheral blast cell count (PBC). Patients with PBC of 50,000 mm-3 or more tended to have more relapses (P = 0.08, Table I ). The probability of remaining in first continuous complete remission (CCR) was significantly lower (P = 0.029). In this retrospective study we found no correlation between age, sex and immunological subtype on the one hand and relapse rate and relapse-free intervals on the other hand. The median follow-up of this group was 8 years (range 0-12 years). P-170 expression was found in 36 out of 104 leukaemias (35%), while 68 patients (65%) failed to express P-170 in the leukaemic cells (Table II) . The proportion of positively stained cells ranged from 1 to 100%. The intensity of staining also varied. Figure la shows a typical immunohistochemical staining of P-170. In our study 38 out of 104 patients (37%) experienced relapses. In the population who experienced relapses, 17 patients (45%) were P-170 positive. In the group without relapses (66 patients) P-1 70-positive cells were seen in only 19 patients (29%) (P = 0.099; Table  II) . A life table analysis for the relapse-free interval of P-170-positive and P-170-negative patients (n = 104) is shown in Figure 2 . Patients with P-170-positive blast cells had a significantly lower probability of first CCR (P = 0.03).
Overexpression of GST-it was present in 52 of the 104 cases (50%). The staining was homogeneous in the cytoplasm (Figure lb) and a high percentage of cells (80-100%) had the same intensity of staining in each sample. GST-t overexpression was detectable in 27 out of 38 patients who experienced relapses (71%). In contrast, in the group without relapses only 25 out of 66 patients (38%) were GST-i positive. The relapse rate was significantly higher in leukaemias with an overexpression of GST-i (P = 0.001, Table II ). The probability of first CCR in the GST-n-positive patients were significantly lower (P = 0.01, Figure 3 ).
Coexpression of P-170 and GST-i was observed in 22 leukaemias (21%). The blast cells of 14 patients (13%) were P-170 positive but GST-i negative. In 30 leukaemias (29%) only a GST-i overexpression was found. In 38 leukaemias (37%) neither P-170 nor GST-it expression was detected. To determine whether the combination of P-170 and GST-n has a higher prognostic significance, the patients were grouped Figure 4 shows that the prognosis of the patients according to the probability of remaining in first CCR is more unfavourable by combining both proteins. Similar results were obtained for the relapse rate (Table III) . Thirteen out of 22 patients (59%) in the group with coexpression of P-170 and GST-i relapsed.
In contrast, only seven of the 38 patients (18%) with no evidence of either resistance protein experienced relapses. Among the 14 patients whose blast cells were P-170 positive but GST-ic-negative, four (29%) experienced relapses; among the 30 patients with GST-ir-positive and P-170-negative blast cells 14 (47%) developed relapses. We further analysed the prognostic impact of P-170 and GST-i on the time to relapse in the presence Figure 2 Kaplan-Meier curves of the relapse-free interval in children with P-170-positive vs P-170-negative ALL.
(PBC) as well as P-170 and GST-ir revealed a highly significant influence of PBC (P =0.00 1) and a borderline significant influence of P-170 (P =0.08), whereas all other factors including GST-i were of no significant influence (P>0.10). An analysis of the reduced model with only PBC and P-170 as covariates resulted in a significant influence of both PBC (P = 0.0001) and P-170 (P = 0.025). The independent effect of P-170 on disease-free survival (in addition to PBC) could be confirmed by an analysis of deviance (deviance= -2 [log likelihood (PBC) -log likelihood (PBC, P-170)] = -2 [(-164.17) -(-161.91)] = 4.52, P<0.05).
P-170 and GST-c were not totally independent of each other (value of the chi-square test for independency = 2.72, P = 0.10). Therefore we checked for a possible prognostic influence of GST-ir in addition to that of PBC and P-170 as well as when replacing P-170 by GST-nc. Both analyses resulted in no significant additional influence of GST-ic (P = > 0.05).
Discussion
Expression of the multidrug resistance gene (MDR-J) or its gene product (P-170) has been found in many human solid Figure 4 Kaplan-Meier curves of the relapse-free interval in children with (1) P-170-negative/GST-n-negative (n = 38), (2) P-170-positive/GST-ir-negative (n = 14), (3) P-170-negative/GST-npositive (n = 30) and (4) P-170-positive/GST-n-positive ALL (n = 22).
tumours (Chan et al., 1990; Efferth et al., 1992; Volm et al., 1992b) and in leukaemias (Pirker et al., 1991; Campos et al., 1992) . Most studies of leukaemias were performed with acute non-lymphoblastic leukaemia (ANLL) (Holmes et al., 1989; Sato et al., 1990) , whereas only few reports on acute lymphoblastic leukaemia (ALL) exist (Rothenberg et al., 1989; Pieters et al., 1992; Goasguen et al., 1993) . Using immunohistochemical methods (Musto et al., 1990) or immunoblot techniques (Kuwazuru et al., 1990 ) P-170 expression was found in six out of 12 and in four out of 11 adult ALL patients respectively. In addition, increased MDR-J mRNA transcripts were found in five of 14 adults with ALL (Gruber et al., 1992) . In a recent work Goasguen et al. (1993) found P-170 expression in 12 out of 36 children (33%) with newly diagnosed ALL. In contrast to these results, Rothenberg et al. (1989) found an expression of P-1 70 in only one out of nine adult ALL patients. Using the monoclonal antibody MRK-16 no expression of P-170 was found in 13 ALL cases (Ito et al., 1989 We found similar significant results using a cut-off point of 5% or 10% P-170-positive cells (data not shown).
We also compared the results of P-170 with the clinical outcome. As response criteria we used the relapse rate and the relapse-free interval. Both parameters reflect the responsiveness to the applied therapy. We found a significantly lower probability of remaining in first continuous complete remission (CCR) (P = 0.033) and a tendency for an increased relapse rate in patients with P-170-positive blast cells (P = 0.099). Similar results were published on adult ALL on the basis of MDR-J mRNA detection (Marie et al., 1991; Gruber et al., 1992 The data indicate that the expression of P-170 is a prognostic factor for both relapse rate and relapse-free interval of patients with ALL in addition to clinical prognostic factors.
Several studies suggest that refractoriness to chemotherapy is only partly caused by P-170 and that other resistance mechanisms are also involved in this process (Moscow et al., 1989; Tiedefelt et al., 1992; Volm et al., 1992a) . Therefore, we also analysed the expression of GST-i in the same patients.
We found increased GST-c levels in the blast cells from 52 of 104 patients (50%). Because of its physiological function GST-i expression was found in all samples at a low level so that only patients with moderate or intensive staining were considered to be positive for GST-7c overexpression. Gekeler et al. (1992) reported moderate GST levels in patients with the initial stage of ALL and with relapsed ALL at the mRNA levels when compared with the cell line CCRF-CEM.
Results obtained on initial stage of non-Hodgkin's lymphoma (NHL) (Rodriguez et al., 1993) and relapsed stage of NHL (Cheng et al., 1993) also suggest an involvement of increased GST-ic levels in drug resistance of lymphatic tumours. Increased levels of GST-ir mRNA have also been observed in untreated adult leukaemias (McQuaid et al., 1989) . Tidefelt et al. (1992) found that 23 of 59 patients with ANLL were positive for GST-I overexpression using the same discriminating criteria for GST-i estimation as in our study. In addition, in 95% of patients with chronic lymphocytic leukaemia (CLL), Schisselbauer et al. (1990) found detectable GST-i levels and a quantitatively increased GST activity in chlorambucil-resistant CLL patients. To our knowledge the present study is the first investigation into the prognostic importance of GST-r in childhood ALL. Our data show an association between increased GST-it levels and a higher relapse rate (P = 0.003) as well as a lower probability of the first CCR (P = 0.01). Furthermore, our study suggests a tendency for simultaneous expression of P-170 and GST-i (P = 0.099) and the two parameters are probably not independent of each other. Similar results were obtained in NHL (Cheng et al., 1993) and in lung tumours (Volm et al., 1991 (Volm et al., , 1992a . In contrast to this, no correlation was found between the parameters in primary NHL (Rodriguez et al., 1993) . Holmes et al. (1990) observed GST-i overexpression independent of MDR-J gene expression. By combing both parameters in our study, the prognostic significance with respect to the relapse-free interval and the relapse rate was improved. In a univariate analysis we showed that P-170-and GST-c overexpression were independent of sex, FAB type, immunological subtype and the peripheral blast cell count. Goasguen et al. (1993) observed a significantly higher expression of P-170 in B-type ALL vs precursor B-ALL. We investigated six patients with B-ALL and found four to be positive for P-170 (unpublished data). In fact, the staining in these cells was more intensive and the proportion of positive cells was higher than in non-B-ALL. B-ALL indeed is known to have different biological and clinical features when compared with non-B-ALL, and so these patients are treated differently. This was the reason why we excluded B-ALL patients from our study.
Although we observed a significant prognostic power of GST-c in the univariate analysis (P = 0.032), this could not be confirmed in the multivariate analysis when PBC and P-170 were included. The effect of GST-ic seems partly to be due to its minor correlation (P = 0.10) with P-170 and possibly higher order effects which have been beyond the aim of this investigation. Thus, our results suggest that only Pglycoprotein has prognostic significance in ALL. In earlier investigations we found that no correlation exists between the expression of dihydrofolate reductase, thymidylate synthase, DNA topoisomerase II or metallothionein and the clinical outcome of children with ALL Stammler et al., 1994; Volm et al., 1994a) .
Since drug resistance remains the major obstacle in the treatment of the lymphoblastic leukaemia, interest has also focused on the elucidation of molecular mechanisms of resistance. Although our knowledge as to which factors are responsible for a regulated coexpression of resistance mechanisms is limited, one possibility is that the resistance factors belong to a set of genes which is controlled by general regulatory mechanisms. Indeed, the c-fos/c-jun protein complex which binds specifically to AP-1 affects the transcriptional expression of several cellular genes. Interestingly, P-glycoprotein and glutathione S-transferase contain an AP-1 motif, thus these genes may also be regulated by the cellular oncogenes c-fos and c-jun (Angel & Karin, 1991; Teeter et al., 1991) . Indeed, in earlier studies (Volm et al., 1994b) we found that the relapse-free intervals were lower in patients with Fos-and Jun-positive leukaemic cells than in patients with Fos-and Jun-negative tumour cells. Additionally, nuclear protein kinase C is of high functional importance as a stimulator of the activity of proto-oncogenes such as c-fos and c-jun. Earlier results of univariate and multivariate analyses demonstrated that in addition to the clinical prognostic indicators protein kinase C is a significant prognostic factor for relapse rate, relapse-free intervals and overall survival times in ALL of children (Volm et al., 1994c 
